WGc-0201 / WestGene Biopharma - LARVOL DELTA

WGc0201-HBV: A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Jiyan Liu | Trial completion date: Jul 2027 ➔ Sep 2031 | Trial primary completion date: Jul 2026 ➔ Sep 2027

Trial completion date • Trial primary completion date • Hepatitis B • Infectious Disease • Inflammation

WGc0201-HBV: A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Jiyan Liu | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2025 ➔ Apr 2026

Enrollment open • Trial initiation date • Hepatitis B • Infectious Disease • Inflammation

Application of HBx-based mRNA vaccine (WGc-0201 injection) in liver cancer liver transplantation (ChiCTR) - P1 | N=12 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital of Sichuan University

New P1 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • Transplantation

mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress. (PubMed, Mol Ther Nucleic Acids) - "Similarly, HBx-biased mRNA vaccines, such as WGc-0201, have recently entered early clinical evaluation without reported clinical efficacy. Despite these advances, several challenges impede effective therapy, including innate-immune overactivation, HBV genotypic diversity, and the need for rational therapeutic combinations. This review summarizes current preclinical findings and emerging clinical evidence and outlines future strategies toward durable viral control and effective prophylaxis, including self-amplifying or cyclic RNAs, receptor-targeted LNPs, and multimodal therapeutic regimens."

First-in-human • Journal • Preclinical • Review • Fibrosis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Inflammation • Oncology • Solid Tumor

An exploratory study on the mRNA WGc-0201 vaccine against advanced hepatitis B related hepatocellular carcinoma in a prospective open-label and first-in-human clinical trial (ESMO 2025) - P1 | "These favorable outcomes provide a proof-of-concept andsupportfurther exploration of WGc-0201. Legal entity responsible for the study The authors."

Clinical • First-in-human • Metastases • P1 data • Hepatocellular Cancer • Oncology • Solid Tumor • IFNG

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: West China Hospital

New P1 trial • Hepatocellular Cancer • Oncology • Solid Tumor